TABLE 1.
Participant characteristics, symptoms during acute infection, and time since molecular confirmed positive COVID-19 test for Long-CoV, no-longer symptomatic (ns)-CoV and Controls. BMI, body mass index; BSA, body surface area; PCFS, Post-COVID Functional Scale; EQ-5D VAS, EuroQol 5-Dimension visual analog scale.
| Self-reported symptom groupings | Long-CoV | Ns-CoV | Control | |
|---|---|---|---|---|
| Sex (F/M), N | 20/8 | 10/4 | 17/7 | |
| Age (years) | 40 (11) | 37 (9) | 41 (12) | |
| Height (cm) | 168 (8) | 170 (8) | 169 (8) | |
| BMI (kg/m2) | 24.7 (3.1) | 23.0 (3.1) | 23.6 (3.2) | |
| BSA (m2) | 1.81 (0.19) | 1.77 (0.20) | 1.77 (0.19) | |
| Smoking History (n) | 4 | 2 | 3 | |
| Pre-existing airway obstruction (n) | 5 | 1 | 1 | |
| Cardiovascular Comorbidity (n) | 3 | 2 | 2 | |
| Acute COVID | Symptom Length (days) | 20 (18) | 19 (17) | - |
| Hospital Admission (n, %) | 4 (13%) | 3 (21%) | - | |
| Emergency Visit (n, %) | 5 (17%) | 2 (14%) | - | |
| Dyspnea (n, %) | 24 (80%) | 13 (93%) | - | |
| Fatigue (n, %) | 26 (87%) | 7 (50%) | - | |
| Fever (n, %) | 20 (67%) | 10 (71%) | - | |
| Anosmia (n, %) | 19 (63%) | 8 (57%) | - | |
| Loss of Taste (n, %) | 18 (60%) | 8 (57%) | - | |
| Muscle Pain (n, %) | 16 (53%) | 11 (79%) | - | |
| Headaches (n, %) | 20 (67%) | 8 (57%) | - | |
| Cough (n, %) | 19 (63%) | 8 (57%) | - | |
| Diarrhea (n, %) | 7 (23%) | 1 (7%) | - | |
| Time post infection | Days post positive test | 214 (85) | 198 (89) | - |
| Quality of Life | PCFS | 1 (1)†‡ | 0 (0) | 0 (0) |
| EQ-5D (VAS) | 71 (16)†‡ | 82 (12) | 89 (9) | |
†: p < 0.05 vs. Con; ‡: p < 0.05 vs. ns-CoV.